News & Views

News and Opinions


Recap of WHO 140th Executive Board meeting

The discussions on antimicrobial resistance (AMR) at the World Health Organization’s (WHO’s) 140th Executive Board meeting, had several interesting interventions from Member States on the key areas that the WHO was given responsibility over in the UNGA Political Declaration on AMR from September 2016.


New collaboration on strategies for tackling antibiotic resistance

ReAct and Stockholm Resilience Centre join forces on the global antibiotic resistance challenge.


ReAct briefings for the 140th WHO Executive Board

For the 140th session of WHO Executive Board, which run from January 23 to February 1, ReAct has developed and shared a briefing document for the agenda point on Antimicrobial Resistance (AMR ) and a number of other relevant agenda points for Member State Missions in Geneva to consider.


The role of faith-based organizations in taking action against antibiotic resistance

Late December 2016 a group of more than 30 experts from the faith based health sector was invited to attend a workshop on strengthening faith-based engagement in “Combating the Emergence and Spread of Antimicrobial Resistance”, at the Vatican.


Bacteriophages as a part of hospital hygiene

Health-care associated infections are troublesome from many aspects, not only are they often more virulent or more resistant but also strike at the heart of health care: people go to the hospital to be cured, only to contract another potentially lethal disease.


ReAct wishes for 2017!

ReAct wishes for 2017, node by node.


Consensus around delinkage emerges - of sorts

A literature review on proposed incentive mechanisms for the R&D of new antibiotics by the EU-US TATFAR has shown a broad consensus on recommending delinkage. However, differences in definition are hiding underneath the consensus.

Laboratory materials on a table.


Bottlenecks of antibiotic research need to be addressed

While problems with antibiotic discovery and development are often discussed in the context of funding and return on investment, these factors are not the only ones. Even if the financial bottlenecks would be resolved, significant scientific and structural problems are still present and need to be addressed. We highlight a few of the scientific bottlenecks in antibiotic discovery, with links to further reading.